We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
From May 2019 to May 2024
By Chris Wack
Alexion Pharmaceuticals Inc. (ALXN) said Wednesday it was buying Achillion Pharmaceuticals Inc. (ACHN) for an initial consideration of $930 million, or $6.30 a share of Achillion common stock.
The companies said as part of the acquisition, Alexion will also be acquiring the cash currently on Achillion's balance sheet. As of Sept. 30, this was about $230 million.
Alexion said the deal includes the potential for additional consideration in the form of non-tradeable contingent value rights, which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These include $1.00 a share for the U.S. FDA approval of danicopan and $1.00 a share for ACH-5228 Phase 3 initiation.
Alexion said the deal will be funded with cash on hand. The transaction is expected to close in the first half of 2020.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 16, 2019 07:09 ET (11:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
